D
David Planchard
Researcher at Institut Gustave Roussy
Publications - 430
Citations - 28831
David Planchard is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 55, co-authored 352 publications receiving 19769 citations. Previous affiliations of David Planchard include Université Paris-Saclay & Princess Margaret Cancer Centre.
Papers
More filters
Journal ArticleDOI
Small cell lung cancer: a slightly less orphan disease after immunotherapy.
Jordi Remon,Mihaela Aldea,Benjamin Besse,David Planchard,Martin Reck,Giuseppe Giaccone,J-C. Soria,J-C. Soria +7 more
TL;DR: In this paper, the authors provide a summary of recent therapeutic advances in SCLC in light of ICIs, as well as current challenges of this strategy in patients who are elderly, have poor performance status or brain metastases.
Journal ArticleDOI
A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations.
Gregory J. Riely,Julie R. Brahmer,David Planchard,Lucio Crinò,Robert C. Doebele,Luis Alberto Mas Lopez,Scott N. Gettinger,C. Schumann,Xiaoyun Li,Barbara Atkins,Scot Ebbinghaus,Rafael Rosell +11 more
TL;DR: Preclinical data support the role of mammalian target of rapamycin (mTOR) in KRAS mediated oncogenesis and ridaforolimus is an inhibitor of mTOR which has been shown to have efficacy in advanced endometrial cancer and soft tissue sarcoma.
Journal ArticleDOI
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer.
Helena A. Yu,Luis Paz-Ares,James Chih-Hsin Yang,Ki Hyeong Lee,Pilar Garrido,Keunchil Park,Joo Hang Kim,Dae Ho Lee,Huzhang Mao,Sameera R. Wijayawardana,Ling Gao,Rebecca R. Hozak,Bo H. Chao,David Planchard +13 more
TL;DR: The combination of the EGFR tyrosine kinase inhibitor (TKI) osimertinib plus the VEGFR2-directed antibody ramucirumab in patients with T790M-positive EGFR-mutant non–small cell lung cancer (NSCLC) demonstrated encouraging safety and antitumor activity.
Journal ArticleDOI
Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non–Small-Cell Lung Cancer
Laura Mezquita,Aurélie Swalduz,Cécile Jovelet,Sandra Ortiz-Cuaran,K. Howarth,David Planchard,V. Avrillon,Gonzalo Recondo,Solène Marteau,Jose Carlos Benitez,Frank de Kievit,Vincent Plagnol,Ludovic Lacroix,Luc Odier,Etienne Rouleau,Pierre Fournel,Caroline Caramella,Claire Tissot,Julien Adam,Samuel Woodhouse,Claudio Nicotra,Edouard Auclin,Jordi Remon,Clive Morris,Emma Green,Christophe Massard,Christophe Massard,Maurice Perol,Luc Friboulet,Benjamin Besse,Benjamin Besse,Benjamin Besse,Pierre Saintigny +32 more
TL;DR: Next-generation, targeted, amplicon-based sequencing for liquid biopsy specimen profiling provides clinically relevant detection of ALK/ROS1 fusions in TKI-naïve patients and allows for the identification of resistance mutations in patients treated with TKIs.
Journal ArticleDOI
Three-year overall survival update from the PACIFIC trial.
Jhanelle E. Gray,A. Villegas,Davey B. Daniel,David Vicente,Shuji Murakami,Rina Hui,Takayasu Kurata,Alberto Chiappori,Ki Hyeong Lee,Byoung Chul Cho,David Planchard,Luis Paz-Ares,Corinne Faivre-Finn,Johan Vansteenkiste,David R. Spigel,Catherine Wadsworth,Maria Taboada,Phillip A. Dennis,Mustafa Ozguroglu,Scott J. Antonia +19 more
TL;DR: In the phase 3 PACIFIC study of patients with unresectable, Stage III NSCLC without progression after chemoradiotherapy (CRT), durvalumab demonstrated significant improvements versu...